NEW ZEALAND GAZETTE

No. 159

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name

(if any)

--- | --- | --- | ---
7.5 mcg Haemophilus influenza type b purified capsular polysaccharide (polyribosylribitol phosphate PRP) and 125 mcg neisseria meningitidis OMPC per 0.5 mL | Solution for injection, single dose vial | Merck & Co Inc., West Point, Pennsylvania, United States of America | Pedvax HIB

Risperidone 1 mg/mL in 100 mL | Solution, oral | Janssen Pharmaceutica n.v., Beerse, Belgium | Risperdal

Cefuroxime sodium equivalent to 250 mg, 750 mg 1.5 g cefuroxime | Powder for injection, vial | Glaxo Operations UK Limited, Barnard Castle, County Durham, United Kingdom | Zinacef

Cefuroxime axetil 125 mg, 250 mg, 500 mg | Tablets | Glaxo Operations UK Limited, Barnard Castle, County Durham, United Kingdom | Zinnat

Dated this 29th day of October 1996.

KAREN O. POUTASI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.

g07053

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name

(if any)

--- | --- | --- | ---
Danthron 25 mg, poloxamer 188 200 mg per 5 mL in 100 mL and 300 mL | Suspension, oral | Regent Laboratories Limited, North Acton, London, England and Universal Products Limited, Lytham, Lancashire, England | Codalax

Danthron 75 mg, poloxamer 188 1 g per 5 mL in 10 mL and 300 mL | Suspension, oral | Regent Laboratories Limited, North Acton, London, England and Universal Products Limited, Lytham, Lancashire, England | Codalax Forte

Note: This consent is valid for two years from the 30th of July 1996.

Dated this 29th day of October 1996.

KAREN O. POUTASI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.

g07055

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name

(if any)

--- | --- | --- | ---
Potassium chloride 3 mmol/mL in 20 mL | Solution for infusion, ampoule | McGaw Biomed Limited, Point Chevalier, Auckland |

Potassium acetate 4 mmol/mL in 20 ml | Solution for infusion, ampoule | McGaw Biomed Limited, Point Chevalier, Auckland |

Amoxicillin trihydrate 286.98 mg, 573.96 mg (equivalent to 250 mg, 500 mg amoxicillin) | Capsules | Apo-Biotics Inc., Weston, Ontario, Canada | Apo-Amoxi

Loratadine 10 mg, pseudoephedrine sulphate 240 mg | Tablet, modified release | Schering-Plough Laboratories N.V., Heist-op-den-Berg, Belgium and Schering-Plough Pty Limited, Baulkham Hills, New South Wales, Australia | Clarinex

Flutamide 250 mg | Tablet | Orion Corporation, Espoo, Finland | Flutol

Note: Not to be marketed as substitutable for any other flutamide tablet as if the two (2) products were bioequivalent.

Miconazole nitrate 2% w/w in 20 g | Powder, topical | Ego Pharmaceuticals Pty Limited, Braeside, Victoria, Australia | Fungo